Traplixam (Triplixam) Causing Hypotension - Alternative Antihypertensive Combinations

• Patient is volume-depleted or dehydrated
• Dose is too high for the patient's baseline BP
• Used in elderly or frail patients

Step 1 - Before Switching: Optimize First

• Reduce to a lower-strength Triplixam (e.g., from 10/2.5/10 down to 5/1.25/5)
• Remove indapamide temporarily if volume depletion is suspected
• Check posture/timing - take in the morning, ensure adequate hydration

Step 2 - Alternative Two-Drug Combinations (Preferred)

Key point: The ACE inhibitor + CCB (without diuretic) combination from ACCOMPLISH study is the preferred first choice and carries less hypotension risk than the triple combination in Traplixam.

Step 3 - Beta-Blocker Based Combinations (Second-Line)

• Beta-blocker + CCB (e.g., Bisoprolol + Amlodipine) - for patients with angina or high heart rate
• Beta-blocker + Thiazide - effective but metabolically unfavorable
• ACE inhibitor/ARB + Beta-blocker - for heart failure with hypertension

Step 4 - If Three Drugs Still Needed (Resistant Hypertension)

• ACE-I/ARB + CCB + low-dose thiazide at minimum effective doses
• Add spironolactone 25 mg as 4th agent for true resistant hypertension (strong evidence)

Causes of Hypotension with Traplixam to Address

Practical Recommendation

Perindopril + Amlodipine (dual combination, no diuretic) - e.g., Coveram 5/5 or 10/5 mg once daily

• Textbook of Family Medicine 9e, Combination Therapy section: "the most compelling evidence suggests that if two agents are required, a combination of an ACE inhibitor plus a calcium channel blocker (amlodipine) should be used first line based on the ACCOMPLISH study."

LVH with Aortic Valve Calcification - Clinical Overview

Pathophysiology - How They Are Linked

"The obstruction to left ventricular outflow leads to gradual narrowing of the valve orifice (valve area ~0.5-1 cm² in severe AS; normal ~4 cm²) and an increasing pressure gradient across the calcified valve. Left ventricular pressures rise to 200 mmHg or more, producing concentric left ventricular (pressure overload) hypertrophy."

"As the valve narrows, increased left ventricular afterload leads to compensatory LVH to maintain cardiac output. LVH and increased wall tension predispose the patient to cardiac ischemia even in the absence of significant coronary artery disease."

Gross Pathology of Calcific Aortic Stenosis

Echocardiography - Diagnostic Standard

Etiology and Risk Factors

Important: Despite similarities to atherosclerosis, statins do NOT prevent progression of valve calcification. The valve contains osteoblast-like cells that synthesize bone matrix proteins - this distinguishes it from atherosclerosis. (Robbins Pathology)

Severity Classification by Echocardiography

• Peak velocity ≥4 m/s: symptoms usually develop within 2 years
• Peak velocity ≥5 m/s: symptoms likely within 1 year
• Calcium score by CT correlates with severity and can resolve discordant echo findings

Classic Symptom Triad (Severe AS - SAD)

1. Syncope - exertional, due to inability to increase cardiac output
2. Angina - subendocardial ischemia from hypertrophied LV; also coronary atherosclerosis (coronary angiography recommended pre-op)
3. Dyspnea - diastolic dysfunction from stiff hypertrophied LV → heart failure

• After angina onset: ~5 years survival
• After syncope onset: ~3 years survival
• After heart failure onset: ~2 years survival

LVH in AS - Key Features

• Concentric (pressure overload) hypertrophy - wall thickness increases, cavity size maintained initially
• Diastolic dysfunction develops early - reduced LV compliance → impaired filling
• The hypertrophied LV is preload-dependent - any volume depletion, diuresis, or dehydration can cause acute decompensation
• Atrial fibrillation is poorly tolerated - loss of atrial kick worsens diastolic filling

Management

Medical Management

From the PROGRESSA study: "Hypertension was shown to accelerate the progression of aortic valve calcification." - treat hypertension aggressively but carefully.

Definitive Treatment - Valve Replacement

• Low/intermediate surgical risk: either option depending on anatomy and patient preference
• High surgical risk / elderly / frail: TAVR preferred
• Transcatheter approach is now standard in most elderly patients with calcific AS

Emergency Management (Decompensated AS)

• Judicious fluid resuscitation - maintain preload
• Restore sinus rhythm if in AF (atrial kick critical)
• Avoid: vasodilators, aggressive diuresis, inotropes (if possible)
• Vasopressor of choice if needed: phenylephrine or norepinephrine
• IABP as bridge to surgery if no response to medical therapy
• Urgent TAVR/SAVR referral

ECG Findings in LVH + AS

• LVH voltage criteria (Sokolow-Lyon: SV1 + RV5 ≥35 mm)
• Strain pattern (ST depression + T-wave inversion in lateral leads V4-V6, I, aVL)
• Left axis deviation
• Left atrial enlargement (P-wave abnormalities)
• LBBB (late stage)
• Atrial fibrillation (late stage)

Summary - Key Clinical Points

1. Aortic valve calcification → progressive stenosis → chronic LV pressure overload → concentric LVH
2. LVH makes the heart stiff and ischemia-prone, even without CAD
3. Treat hypertension (ACE-I/ARB preferred) but start low and go slow - the fixed obstruction is unforgiving with vasodilators
4. Statins do NOT slow valve calcification despite atherosclerosis-like risk factors
5. Once symptomatic, only valve replacement (SAVR or TAVR) improves prognosis
6. The LVH may partly regress after successful valve replacement